Kura Oncology (NASDAQ:KURA) Releases Earnings Results, Misses Expectations By $0.03 EPS

Kura Oncology (NASDAQ:KURA) posted its earnings results on Thursday. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.03), Briefing.com reports. Kura Oncology’s revenue for the quarter was up .0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.50) EPS.

Kura Oncology Trading Up 0.2 %

KURA stock traded up $0.04 during trading on Friday, reaching $20.63. 605,625 shares of the stock were exchanged, compared to its average volume of 1,285,810. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $1.57 billion, a price-to-earnings ratio of -9.92 and a beta of 0.89. The business has a 50 day moving average price of $20.65 and a 200-day moving average price of $15.85. Kura Oncology has a 1 year low of $7.41 and a 1 year high of $24.17.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price target on shares of Kura Oncology in a report on Friday. Wedbush reissued an “outperform” rating and set a $37.00 target price on shares of Kura Oncology in a report on Friday. StockNews.com cut Kura Oncology from a “hold” rating to a “sell” rating in a research report on Monday, April 15th. Finally, JMP Securities raised their price objective on Kura Oncology from $22.00 to $32.00 and gave the company a “market outperform” rating in a report on Wednesday, January 31st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Kura Oncology currently has an average rating of “Moderate Buy” and a consensus target price of $28.28.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.